Last edition
News about "Strides Pharma Science Ltd has posted a strong per"
Strides Pharma Q1 FY26 PAT Soars 81% YoY; EBITDA Margin Expands to 19.5%
Strides Pharma Science Ltd has reported a robust financial performance for the first quarter of FY26, with consolidated revenue reaching INR 1,119.7 crore — a 6.2 percent increase from INR 1,053.9 crore recorded in the same quarter of the previous fiscal year.
Strides Pharma Science Ltd Has Posted A Strong Per | 30/07/2025 | By Darshana | 221
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members